Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.
Summary of "Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer."
Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.Prostate Cancer and Prostatic Diseases advance online publication, 17 May 2011; doi:10.1038/pcan.2011.24.
Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
This article was published in the following journal.
Name: Prostate cancer and prostatic diseases
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21577233
- DOI: http://dx.doi.org/10.1038/pcan.2011.24
In the last 10 years, metastatic castration-resistant prostate cancer (mCRPC) treatment has completely changed. Several new agents have been shown to increase mCRPC patients' overall survival. The imp...
Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer.
Successful phenotype-genotype correlation is critically dependent on precise definition and reporting of end points in clinical trials. An uniform nomenclature for "deep phenotyping" of metastatic sit...
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. This trial...
Enzalutamide is a novel antiandrogen which is approved for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy. The efficacy of enzalutamide after...
Prostate cancer is the most common malignancy in Western Europe, of which approximately 10-20% presents with advanced or metastatic disease. Initial response with androgen deprivation therapy is almos...
The purpose of this study is to evaluate the safety and tolerability of JNJ-56021927 in Japanese participants with metastatic castration-resistant prostate cancer (mCRPC- prostate cancer t...
The standard of care for patients with bone-metastatic, castrate-resistant prostate cancer is chemotherapy. If a patient elects not to choose chemotherapy, 70% will progress within 6 mont...
This is an open-label, multicenter, Phase 1/2 study of TAK-700 in combination with docetaxel and prednisone that will evaluate the safety and pharmacokinetics (PK) of the combination and w...
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate can...
Medical and Biotech [MESH] Definitions
Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
A culture-specific acute delusional syndrome occurring mostly in the Malay people and Southern Chinese. The syndrome is characterized by the individual's sudden experience of depersonalization depicted by the belief that his penis is shrinking into his abdomen and that he will die when this occurs. Although generally classified as a culture-specific syndrome, koro may be no more than a variant of castration anxiety (ANXIETY, CASTRATION) as it has been described in non-Asian patients.